IOVA — IOVANCE BIOTHERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1425205 ·
Last close
$14.62
Market Cap
$6.62B
52W High
$15.30
52W Low
$1.76
ADV30
16,643,380
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 71,430,000 | 28,932,000 | -81,043,000 | -79,045,000 | 925,665,000 | 196,508,000 | 203,911,000 |
| Dec 2025 | 86,771,000 | 43,660,000 | -73,460,000 | -71,904,000 | 913,170,000 | 163,078,000 | 214,587,000 |
| Sep 2025 | 67,455,000 | 28,978,000 | -89,758,000 | -91,253,000 | 904,948,000 | 158,134,000 | 202,661,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-270,788,000
Investing CF
$43,023,000
Financing CF
$251,793,000
CapEx
$-34,233,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.73
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,854,575,000
Inventory
$58,376,000
Receivables
$81,758,000
ST Investments
$116,935,000
EBIT TTM
$-358,035,000
Pretax Income TTM
$-354,758,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$324,968,992
EBITDA
$-259,603,008
Free Cash Flow
$-187,794,752
Enterprise Value
$3,643,885,312
Total Cash
$297,673,984
Total Debt
$46,003,000
Shares Out
452,971,432
Trailing EPS
$-0.69
Book Value
$1.62
ROE
-40.4%
ROA
-20.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 263,502,000 | -398,213,000 | -390,978,000 | 913,170,000 | 214,587,000 | 698,583,000 | -302,408,000 |
| Dec 2024 | 164,070,000 | -395,278,000 | -372,177,000 | 910,426,000 | 200,021,000 | 710,405,000 | -352,977,000 |
| Dec 2023 | 1,189,000 | -460,559,000 | -444,037,000 | 780,351,000 | 195,738,000 | 584,613,000 | -361,820,000 |
| Dec 2022 | 0 | -398,878,000 | -395,893,000 | 663,982,000 | 164,344,000 | 499,638,000 | -292,757,000 |
TTM Snapshot
Revenues TTM
$285,608,000
NetIncome TTM
$-353,860,000
OpCashFlow TTM
—
Assets (Latest)
$925,665,000
Forward EPS
$-0.29
Max Pain — expiry 2026-10-16
max pain strike: $11.00 · spot: $14.62 · call oi: 12,802 · put oi: 4,782
Expected Move to 2026-10-16:
±$1.27
(8.72%) —
implied range
$13.34 –
$15.89
· ATM straddle on $14.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMVT | Immunovant, Inc. | $6.29B | $30.47 | — |
| KOD | Kodiak Sciences Inc. | $6.28B | $99.87 | — |
| CGON | CG Oncology, Inc. | $5.66B | $63.82 | — |
| CRSP | CRISPR Therapeutics AG | $5.16B | $53.39 | — |
| SRRK | Scholar Rock Holding Corp | $5.14B | $42.19 | — |
News headlines (Yahoo Finance, 1h cache)
Why Iovance Biotherapeutics (IOVA) Effortlessly Soared 256% in Q3
2026-10-04 04:56 · Yahoo
Iovance Biotherapeutics (IOVA) Stock Gets Fair Value Boost On Amtagvi Demand And Margin Outlook
2026-10-03 21:07 · Yahoo
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
2026-10-01 11:00 · Yahoo
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
2026-09-30 10:12 · Yahoo
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
2026-09-30 03:47 · Yahoo
Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
2026-09-30 02:57 · Yahoo
Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth
2026-09-29 16:06 · Yahoo
IOVA Stock Hits Over 2-Year Highs – Why Iovance Raised Its FY2026 Revenue Outlook
2026-09-29 14:15 · Yahoo
Iovance Raises 2026 Revenue Guidance to $410 Million-$420 Million
2026-09-29 13:33 · Yahoo
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
2026-09-29 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.